Clinical Trial Update: Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE) [Phase 2]

View source ↗

Summary

Phase 2 open-label extension study of losmapimod for facioscapulohumeral muscular dystrophy reports efficacy and safety results; the trial is terminated with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Facioscapulohumeral Muscular Dystrophy

Drugs mentioned

• Losmapimod (losmapimod)

Snippet

Sponsor: Fulcrum Therapeutics | Conditions: Facioscapulohumeral Muscular Dystrophy (FSHD) | Phase 2 | Status: TERMINATED | Results posted: 2025-09-30